Welcome to the Multiple Myeloma Resource Center! Here you’ll find current information, news items, highlights from the literature, and other resources that focus on multiple myeloma and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.


Charise Gleason, MSN, NP-C, AOCNP Winship Cancer Institute of Emory University Nell Hodgson Woodruff School of Nursing at Emory Healthcare	Amy Pierre, MSN, RN, ANP-BC Memorial Sloan Kettering Cancer Center Myeloma/Lymphoma Division Flatiron Health Real World Evidence Research Oncology

Role of the Clinical Pharmacist in Multiple Myeloma Management

Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit

Disparities in Healthcare

International Myeloma Working Group Immunotherapy Committee Consensus Guidelines and Recommendations for Optimal Use of T-Cell-Engaging Bispecific Antibodies In Multiple Myeloma

Dietary and Microbiome Evidence in Multiple Myeloma and Other Plasma Cell Disorders

Frontiers in Oncology

Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma

Blood Cancer Journal

Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study

Frontiers in Immunology

Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy

Clinical Lymphoma, Myeloma & Leukemia

Long-term progression-free survival in patients treated with RVD induction and risk-adapted maintenance

Cureus

Rare extramedullary manifestations of multiple myeloma: a case series involving the thyroid, pleura, and skin

British Journal of Haematology

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

Blood Cancer Journal

Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma

Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

Annals of Medicine and Surgery

Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study

Clinica Chimica Acta; International Journal of Clinical Chemistry

Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

Multiple Myeloma Resource Center

The New Role of MRD Testing in Trials and Treatments

Role of the Clinical Pharmacist in Multiple Myeloma Management

Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit

Disparities in Healthcare

International Myeloma Working Group Immunotherapy Committee Consensus Guidelines and Recommendations for Optimal Use of T-Cell-Engaging Bispecific Antibodies In Multiple Myeloma

Dietary and Microbiome Evidence in Multiple Myeloma and Other Plasma Cell Disorders

Frontiers in Oncology

Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma

Blood Cancer Journal

Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study

Frontiers in Immunology

Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy

Clinical Lymphoma, Myeloma & Leukemia

Long-term progression-free survival in patients treated with RVD induction and risk-adapted maintenance

Cureus

Rare extramedullary manifestations of multiple myeloma: a case series involving the thyroid, pleura, and skin

British Journal of Haematology

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

Blood Cancer Journal

Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma

Lancet

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

Annals of Medicine and Surgery

Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study

Clinica Chimica Acta; International Journal of Clinical Chemistry

Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

Treatment of Early Relapsed Multiple Myeloma with Iberdomide, Daratumumab and Dexamethasone

Mezigdomide in Triple-Class Relapsed/Refractory Multiple Myeloma

Treatment of Newly Diagnosed Multiple Myeloma